BMY Bristol-Myers Squibb
- Official Name: BRISTOL-MYERS SQUIBB CO
- Headquarters: Route 206 And Province Line Road, PRINCETON, NJ, 08543 US
- CEO: Christopher S. Boerner
- Website: bms.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-14 | 1 | Won by 3.518 | 0.935 - (2.583) | ||
| 2025-07-15 | 1R | Won by 1.377 | (1.410) - (2.787) | ||
| 2025-07-21 | 2 | Lost by 6.952 | (0.271) - 6.681 | ||
| 2025-07-23 | 1R | Lost by 2.971 | 1.577 - 4.548 | ||
| 2025-07-28 | 3 | Won by 2.485 | 2.169 - (0.316) | ||
| 2025-07-29 | 2R | Lost by 6.258 | (3.655) - 2.603 | ||
| 2025-08-04 | 4 | Won by 1.256 | (2.888) - (4.144) | ||
| 2025-08-07 | 1R | Won by 0.590 | 1.610 - 1.020 | ||
| 2025-08-11 | 5 | Won by 2.906 | 2.191 - (0.715) | ||
| 2025-08-18 | 6 | Won by 3.580 | 4.581 - 1.001 | ||
| 2025-08-21 | 2R | Won by 2.213 | 0.522 - (1.691) | ||
| 2025-08-25 | 7 | Lost by 7.313 | (3.043) - 4.270 | ||
| 2025-09-01 | 8 | Won by 0.001 | 0.115 - 0.114 | ||
| 2025-09-04 | 3R | Lost by 5.040 | (1.732) - 3.308 | ||
| 2025-09-08 | 9 | Lost by 2.939 | (1.084) - 1.855 | ||
| 2025-09-15 | 10 | Won by 3.970 | (0.840) - (4.810) | ||
| 2025-09-22 | 11 | Lost by 2.547 | (2.603) - (0.056) | ||
| 2025-09-29 | 12 | Lost by 0.177 | (1.649) - (1.472) | ||
| 2025-10-06 | 13 | Won by 6.147 | 1.608 - (4.539) | ||
| 2025-10-13 | 14 | Won by 0.803 | (3.306) - (4.109) | ||
| 2025-10-20 | 15 | Lost by 2.707 | 0.119 - 2.826 |
Latest News
AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors?
AbbVie's stock has surged nearly 29% this year, but a rising share price compresses the yield even as the dividend keeps growing. Before adding s...
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's ...
When Amgen's Forecast And Chart Say The Same Thing, Pay Attention
Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock has gained 15.2%, outpacin...
Gilead’s HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next?
Gilead Sciences (GILD) built its foundation on HIV treatment. Biktarvy alone accounted for $14.3 billion of the company's $29.4 billion in fiscal...
Is Amgen Stock Increasing Your Market Risk?
Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that position with broad exposure to...
Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know
Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff and $43 billion in debt put the pace of future increase...
Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside?
Over the last year, Bristol-Myers Squibb Company (NYSE:BMY) has done better than the overall market, with its shares increasing by nearly 40% as a res...
How Positive Phase 3 Results Will Impact Bristol Myers Squibb Stock Investors
Bristol Myers Squibb recently reported positive Phase 3 topline data across three late stage programs, including RYZ101 in GEP NETs, admilparant in id...
Bristol Myers Squibb: The New Portfolio Is Starting To Carry More Of The Business
Bristol Myers Squibb is executing a visible portfolio transition, with its Growth Portfolio now surpassing Legacy Portfolio. Read more on BMY stock he...
How Has Merck's Story Changed?
Investors are pricing Merck (MRK) stock at 5.5 times sales, compared with 3.1 for the S&P 500. Shareholders paying that premium need to understand...
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three nov...
Bristol-Myers Squibb's Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
Bristol-Myers Squibb's (BMY) LPA1 antagonist admilparant can still be viable despite recent mixed re
A $600,000 Dividend Portfolio Has a $52,900 Tax Problem. Here’s the Roth Solution
Six popular dividend stocks sitting in a taxable account quietly hand a portion of every payout to the IRS, and the gap between what you earn and what...
How Mixed Admilparant Results and Strong Oncology Data Will Impact Bristol Myers Squibb (BMY) Investors
Earlier this week, Bristol Myers Squibb reported positive Phase 3 results for three key programs: RYZ101 in advanced gastroenteropancreatic neuroendoc...
These S&P500 stocks are gapping in today's session
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Thursday to uncover the ...
Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs, BsAbs, CAR-Ts, Aurora Kinase Inhibitors, and EZH2 Inhibitors | DelveInsight
Recently published Neuroendocrine Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, neuroe...
Alto Neuroscience: Doubts Around Depression Candidate Merit Downgrade To Hold
Alto Neuroscience, Inc. pivots to ALTO-207 for treatment-resistant depression; learn risks, catalysts, dilution, and outlook. Click for this ANRO stoc...
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
New types of bispecifics, ADCs and CAR-Ts are still proving themselves in the clinic — pharma’s betting billions anyway.
What Could Send Regeneron Stock Higher?
Regeneron Pharmaceuticals (REGN) may get its next boost from an old deal rather than a new drug. Through the first half of 2026, Regeneron was paying ...
Top S&P500 movers in Wednesday's session
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wed...
These 4 Dividend Stocks Passed the 2020 Stress Test. Are They Buys in Now October?
Four companies kept raising their dividends even as the pandemic hammered their sectors in 2020, and they are still raising today. The question is whe...
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wed...
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
MRK's Keytruda sales growth, earlier-stage launches and expanded indications could boost Q3 results, but biosimilar competition looms in 2028-202...
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
CIBC to launch additional U.S. Canadian Depositary Receipts
Today, CIBC announced its intention to list 11 new U.S. Canadian Depositary Receipts ("CDRs") on the TSX, with trading expected to begin on ...
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this lis...
Is Amgen Stock Worth More Than Its Competitors?
Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and Bristol-Myers Squibb. ...
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes ...
What Does Bristol-Myers Squibb Offer That Pfizer Does Not?
Pfizer (PFE) and Bristol-Myers Squibb (BMY) are bought for the same underlying reason: the search for new drugs to replace older ones losing market ex...
BMY Reports Mixed Phase III Trial Results, Stock Down
Bristol Myers Squibb reports mixed Phase III results for admilparant in IPF, while RYZ101 delivers a significant win in advanced GEP-NETs.
Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans.
Treatment for a serious lung disease failed to meet the company’s primary goal.
Bristol Myers Squibb (BMY) Stock Trades At A Discount Following Its 38% Run
Bristol-Myers Squibb has delivered a strong 38.1% share price gain over the past year, even as shorter term moves have been weaker. This naturally rai...
What Could Bristol Myers Squibb (BMY) Two Phase 3 Wins Change?
Bristol Myers Squibb (NYSE:BMY) reported positive Phase 3 data for admilparant in idiopathic pulmonary fibrosis and RYZ101 in gastroenteropancreatic n...
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transac...
BlackLine Honors Global Enterprise Leaders Transforming Financial Operations
BlackLine’s 2026 Modern Accounting Awards Recognize Booking Holdings, Bristol Myers Squibb, James Hardie, LAZ Parking, Payoneer, and US FoodsLOS ANG...
Kraft Heinz, T-Mobile, Otis, Hasbro and Citi Named Among Newsweek’s America’s Greenest Companies 2027
New ranking recognizes 650 U.S. companies for performance in environmental sustainabilityNEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Newsweek, in part...
Advancing Access to Lung Cancer Care Through Artificial Intelligence Innovation
Originally published on preventcancer.orgThis post has been sponsored by Bristol Myers Squibb as part of its sponsorship of the 2026 Prevent Cancer Ga...
Why A Biotech M&A Wave May Hit This Winter
Biotech stocks have slumped from their August highs. But experts say renewed M&A, likely coming, could catalyze them.
More Than 125 Technology Leaders Registered for HMG Strategy's 19th Annual Greenwich C-Level Technology Leadership Summit on October 15
With Just Two Days Remaining, Qualified Technology Executives Are Encouraged to Register in AdvanceFAIRFIELD, Conn., Oct. 13, 2026 (GLOBE NEWSWIRE) --...
Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $60
Wells Fargo analyst Mohit Bansal maintains Bristol-Myers Squibb (NYSE:BMY) with a Equal-Weight and lowers the price target from $65 to $60.
Bristol-Myers Squibb's Quarterly Earnings Preview: What You Need to Know
Bristol-Myers Squibb is set to announce its third-quarter earnings later this month, and analysts expect the company's bottom line to shrink by a...
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
Bristol Myers Squibb (BMY) reached $57.6 at the closing of the latest trading day, reflecting a -2.58% change compared to its last close.
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He
Bristol Myers Stock Tumbles on ‘Confounding’ Trial Results
Bristol Myers Squibb is making a $4.1 billion bet on radiopharmaceutical cancer drugs ahead of a major patent cliff in 2028.
BMY Stock Drops As Lower-Dose Lung Drug Succeeds In Trial, Higher Dose Misses
Bristol Myers reported that its late-stage ALOFT-IPF trial of the oral drug admilparant met the primary endpoint at the 60 mg twice-daily dose in pati...